Key result
LU 135252 reduces RV pressure ~35% vs saline in rats with pulmonary hypertension.
Why the study?
Does the ETA-receptor antagonist LU 135252 improve survival and pulmonary hemodynamics in rats with established monocrotaline-induced pulmonary hypertension?
Population
Rats with established monocrotaline (MCT)-induced pulmonary hypertension (2 weeks post-MCT injection)
Comparison
LU 135252 50 mg/kg daily oral therapy for 20 days vs Saline
Design
Preclinical
Follow-up
20 days
Authors
Loading...
ETA antagonism should not change clinical practice in pulmonary hypertension; extends preclinical data but leaves human translation open.
Does the ETA-receptor antagonist LU 135252 improve survival and pulmonary hemodynamics in rats with established monocrotaline-induced pulmonary hypertension?
Absolute Event Rate: 53.5% vs 82.5%
p-value: p=<.01
In a rat model of established pulmonary hypertension, ETA-receptor antagonism with LU 135252 improved pulmonary hemodynamics and right ventricular hypertrophy.
Dupuis et al. (1999) studied Monocrotaline-induced pulmonary hypertension. LU 135252 vs. Saline was evaluated on Right ventricular pressure (mmHg) (p=<.01). In rats with established monocrotaline-induced pulmonary hypertension, daily oral therapy with LU 135252 significantly reduced right ventricular pressure compared to saline (53.5 vs 82.5 mmHg; P<0.01).